Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Integrated experimental and simulation study of the response to sequential treatment with erlotinib and gemcitabine in pancreatic cancer.

Ubezio P, Falcetta F, Carrassa L, Lupi M.

Oncotarget. 2016 Mar 29;7(13):15492-506. doi: 10.18632/oncotarget.7491.

2.

Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma.

Lue HW, Cole B, Rao SA, Podolak J, Van Gaest A, King C, Eide CA, Wilmot B, Xue C, Spellman PT, Heiser LM, Tyner JW, Thomas GV.

Oncotarget. 2015 Dec 29;6(42):44675-87. doi: 10.18632/oncotarget.5971.

3.

Dasatinib blocks transcriptional and promigratory responses to transforming growth factor-beta in pancreatic adenocarcinoma cells through inhibition of Smad signalling: implications for in vivo mode of action.

Bartscht T, Rosien B, Rades D, Kaufmann R, Biersack H, Lehnert H, Gieseler F, Ungefroren H.

Mol Cancer. 2015 Nov 21;14:199. doi: 10.1186/s12943-015-0468-0.

4.

Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.

Nagathihalli NS, Castellanos JA, Shi C, Beesetty Y, Reyzer ML, Caprioli R, Chen X, Walsh AJ, Skala MC, Moses HL, Merchant NB.

Gastroenterology. 2015 Dec;149(7):1932-1943.e9. doi: 10.1053/j.gastro.2015.07.058. Epub 2015 Aug 7.

PMID:
26255562
5.

The Roles of ROS and Caspases in TRAIL-Induced Apoptosis and Necroptosis in Human Pancreatic Cancer Cells.

Zhang M, Harashima N, Moritani T, Huang W, Harada M.

PLoS One. 2015 May 22;10(5):e0127386. doi: 10.1371/journal.pone.0127386. eCollection 2015.

6.

Mechanisms underlying the cytotoxicity of a novel quinazolinedione-based redox modulator, QD232, in pancreatic cancer cells.

Pathania D, Kuang Y, Sechi M, Neamati N.

Br J Pharmacol. 2015 Jan;172(1):50-63. doi: 10.1111/bph.12855.

7.

Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.

Formisano L, Nappi L, Rosa R, Marciano R, D'Amato C, D'Amato V, Damiano V, Raimondo L, Iommelli F, Scorziello A, Troncone G, Veneziani B, Parsons SJ, De Placido S, Bianco R.

Breast Cancer Res. 2014 May 5;16(3):R45. doi: 10.1186/bcr3650.

8.

Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant pancreatic cancer MIA PaCa-2 cells.

Duong HQ, Yi YW, Kang HJ, Bae I, Jang YJ, Kwak SJ, Seong YS.

Int J Oncol. 2014 Jun;44(6):2132-8. doi: 10.3892/ijo.2014.2357. Epub 2014 Mar 21.

9.

Genetic Interactions of STAT3 and Anticancer Drug Development.

Fang B.

Cancers (Basel). 2014 Mar 6;6(1):494-525. doi: 10.3390/cancers6010494.

10.

Novel mechanistic insights into ectodomain shedding of EGFR Ligands Amphiregulin and TGF-╬▒: impact on gastrointestinal cancers driven by secondary bile acids.

Nagathihalli NS, Beesetty Y, Lee W, Washington MK, Chen X, Lockhart AC, Merchant NB.

Cancer Res. 2014 Apr 1;74(7):2062-72. doi: 10.1158/0008-5472.CAN-13-2329. Epub 2014 Feb 11.

11.

Epstein-Barr Virus encoded LMP1 regulates cyclin D1 promoter activity by nuclear EGFR and STAT3 in CNE1 cells.

Xu Y, Shi Y, Yuan Q, Liu X, Yan B, Chen L, Tao Y, Cao Y.

J Exp Clin Cancer Res. 2013 Nov 13;32:90. doi: 10.1186/1756-9966-32-90.

12.

MicroRNA let-7 downregulates STAT3 phosphorylation in pancreatic cancer cells by increasing SOCS3 expression.

Patel K, Kollory A, Takashima A, Sarkar S, Faller DV, Ghosh SK.

Cancer Lett. 2014 May 28;347(1):54-64. doi: 10.1016/j.canlet.2014.01.020. Epub 2014 Jan 31.

13.

Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression.

Secord AA, Teoh D, Jia J, Nixon AB, Grace L, Adams DJ, Murphy SK.

Int J Gynecol Cancer. 2014 Feb;24(2):218-25. doi: 10.1097/IGC.0000000000000056.

14.

Tanshinone-1 induces tumor cell killing, enhanced by inhibition of secondary activation of signaling networks.

Xu L, Feng JM, Li JX, Zhu JM, Song SS, Tong LJ, Chen Y, Yang XY, Shen YY, Lian FL, Li YP, Lin DH, Ding J, Miao ZH.

Cell Death Dis. 2013 Nov 7;4:e905. doi: 10.1038/cddis.2013.443.

15.

Emerging targets in pancreatic cancer: epithelial-mesenchymal transition and cancer stem cells.

Castellanos JA, Merchant NB, Nagathihalli NS.

Onco Targets Ther. 2013 Sep 13;6:1261-7. doi: 10.2147/OTT.S34670. Review.

16.

Triterpenes from Poria cocos suppress growth and invasiveness of pancreatic cancer cells through the downregulation of MMP-7.

Cheng S, Eliaz I, Lin J, Thyagarajan-Sahu A, Sliva D.

Int J Oncol. 2013 Jun;42(6):1869-74. doi: 10.3892/ijo.2013.1902. Epub 2013 Apr 16. Erratum in: Int J Oncol. 2014 May;44(5):1781. Thyagarajan-Sahu, Anita [added].

17.

A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.

Hong DS, Choe JH, Naing A, Wheler JJ, Falchook GS, Piha-Paul S, Moulder SL, George GC, Choe JM, Strauss LC, Gallick GE, Kurzrock R.

Invest New Drugs. 2013 Aug;31(4):918-26. doi: 10.1007/s10637-012-9898-3. Epub 2012 Nov 20.

18.

Dynamic phosphorylation of tyrosine 665 in pseudopodium-enriched atypical kinase 1 (PEAK1) is essential for the regulation of cell migration and focal adhesion turnover.

Bristow JM, Reno TA, Jo M, Gonias SL, Klemke RL.

J Biol Chem. 2013 Jan 4;288(1):123-31. doi: 10.1074/jbc.M112.410910. Epub 2012 Oct 26.

19.

Smoking induces epithelial-to-mesenchymal transition in non-small cell lung cancer through HDAC-mediated downregulation of E-cadherin.

Nagathihalli NS, Massion PP, Gonzalez AL, Lu P, Datta PK.

Mol Cancer Ther. 2012 Nov;11(11):2362-72. doi: 10.1158/1535-7163.MCT-12-0107. Epub 2012 Aug 29.

20.

Concomitant targeting of EGF receptor, TGF-beta and SRC points to a novel therapeutic approach in pancreatic cancer.

Deharvengt S, Marmarelis M, Korc M.

PLoS One. 2012;7(6):e39684. doi: 10.1371/journal.pone.0039684. Epub 2012 Jun 27.

Items per page

Supplemental Content

Write to the Help Desk